文献速递前列腺癌

定义有利中间风险前列腺癌:磁共振成像与基因组检测的潜在效用

Defining Prostate Cancer at Favorable Intermediate Risk: The Potential Utility of Magnetic Resonance Imaging and Genomic Tests.
PubMed 文献 · J Urol · 2019-06-07

本研究纳入509例根治性前列腺切除术患者,术前接受多参数磁共振成像、术后接受Decipher®前列腺癌检测,按NCCN风险分层分为有利中间风险125例与不利中间风险171例,分析各变量预测不良病理(Gleason分级组>2、pT3b或pN1)的效用。多变量分析中有利中间风险与Decipher检测保持独立预测价值,多参数磁共振成像未达统计学显著性(p=0.059)。

要点

  • 多参数磁共振成像与Decipher检测有助于更好定义有利中间风险患者的不良病理风险。
  • 多变量分析中有利中间风险和Decipher检测为独立预测因子,多参数磁共振成像p=0.059。
  • 有利中间风险且高基因组风险患者不良病理率42.1%,不利中间风险为39.8%(p=0.56)。

核心结论

  • 多参数磁共振成像与Decipher检测使我们能更好地定义有利中间风险前列腺癌患者的不良病理风险。

研究设计与样本

  • 从本机构数据库纳入509例接受根治性前列腺切除术、术前有多参数磁共振成像且术后有Decipher®前列腺癌检测的患者。
  • 按NCCN风险分层,有利中间风险125例,不利中间风险171例。
  • 采用单变量和多变量二元逻辑回归分析各变量预测不良病理(Gleason分级组>2、pT3b或pN1)的效用。

主要发现

  • 单变量分析中有利中间风险、多参数磁共振成像和前列腺癌检测均显著预测不良病理。
  • 多变量分析中有利中间风险和前列腺癌检测保持独立预测价值,多参数磁共振成像未达统计学显著性(p=0.059)。
  • 有利中间风险且高基因组风险的19例患者不良病理率为42.1%,不利中间风险患者为39.8%(p=0.56)。
  • 低基因组风险患者不良病理率为7.5%,极低或低风险患者为10.2%(p=0.84)。
  • 有利中间风险但高多参数磁共振成像和基因组风险的31例患者不良病理率为25.8%,不利中间风险患者为39.8%(p=0.14)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We determined whether prostate multiparametric magnetic resonance imaging and genomic biomarkers might help further define patients with favorable intermediate risk prostate cancer which could safely be considered suitable for active surveillance. MATERIALS AND METHODS: From our institutional database we identified 509 patients who underwent radical prostatectomy with preoperative magnetic resonance imaging and a postoperative Decipher® prostate cancer test. According to the NCCN® (National Comprehensive Cancer Network®) risk stratification 125 men had favorable intermediate and 171 had unfavorable intermediate risk disease. Univariable and multivariable binary logistic regression analyses were done to test the utility of different variables in predicting adverse pathology, defined as Gleason Grade Group greater than 2, pT3b or pN1. RESULTS: On univariable analysis favorable intermediate risk, multiparametric magnetic resonance imaging and the prostate cancer test significantly predicted adverse pathology. On multivariable analysis favorable intermediate risk and the prostate cancer test maintained independent predictive value while multiparametric magnetic resonance imaging did not meet statistical significance (p = 0.059). The 19 patients at favorable intermediate risk with high genomic risk had an adverse pathology rate slightly higher than patients at unfavorable intermediate risk (42.1% vs 39.8%, p = 0.56). Those at low genomic risk had an adverse pathology rate slightly lower than patients at very low or low risk (7.5% vs 10.2%, p = 0.84). The 31 patients at favorable intermediate risk but at high multiparametric magnetic resonance imaging and genomic risk had an adverse pathology rate slightly lower than patients at unfavorable intermediate risk (25.8% vs 39.8%, p = 0.14). Those at low multiparametric magnetic resonance imaging and genomic risk had an adverse pathology rate slightly lower than patients at very low or low risk (8.5% vs 10.2%, p = 0.89). CONCLUSIONS: Multiparametric magnetic resonance imaging and the Decipher test allowed us to better define the risk of adverse pathology in patients at favorable intermediate risk who were diagnosed with prostate cancer.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Falagario UG, Beksac AT, Martini A, et al. Defining Prostate Cancer at Favorable Intermediate Risk: The Potential Utility of Magnetic Resonance Imaging and Genomic Tests. J Urol. 2019. PMID: 30730408. doi:10.1097/JU.0000000000000134

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。